Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.
about
Impact of rhinitis on airway inflammation: biological and therapeutic implicationsEmerging role of antileukotriene therapy in allergic rhinitisAntileukotrienes in upper airway inflammatory diseasesAllergic inflammation in the unified airway: start with the noseEffects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitisEffects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis.Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs.Role of Leukotrienes and Leukotriene Modifiers in Asthma.Pharmacology and safety of the leukotriene antagonists.Experimental models in asthma.Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma?New perspectives for asthma treatment: anti-leukotriene drugs.The role of leukotrienes in the regulation of tone and responsiveness in isolated human airways.Leukotriene bronchoconstriction induced by allergen and exercise.Measurement of leukotrienes in humans.Montelukast: a review of its therapeutic potential in persistent asthma.Salt intake, asthma, and exercise-induced bronchoconstriction: a review.The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood.Anti-allergic action of anti-malarial drug artesunate in experimental mast cell-mediated anaphylactic models.FcεR1-mediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment.The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthmaSecond-generation antihistamines in asthma therapy: is there a protective effect?Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age.Exercise-induced bronchospasm in the elite athlete.Treating the allergic patient: think globally, treat globally.Effects of mitogen-activated protein kinase kinase inhibitor PD 098059 on antigen challenge of guinea-pig airways in vitroIntroduction to nasal and pulmonary allergy cascade.Adenosine monophosphate bronchial provocation and the actions of asthma therapy.Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues.New insights into the role of the mast cell in asthma.Exposure of healthy volunteers to swine house dust increases formation of leukotrienes, prostaglandin D2, and bronchial responsiveness to methacholine.The re-emergence of the mast cell as a pivotal cell in asthma pathogenesis.A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations.Inflammatory basis of exercise-induced bronchoconstrictionManaging co-morbid asthma with allergic rhinitis: targeting the one-airway with leukotriene receptor antagonists.Reflex regulation of airway smooth muscle tone.Rhinitis, sinusitis and asthma: hard to dissociate?Using guinea pigs in studies relevant to asthma and COPD.Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acidsThe link between allergic rhinitis and asthma: the united airways disease.
P2860
Q24798667-A614A2DA-EACB-4CF0-9F01-A7B04BBEC7A6Q28191844-3CEBE07F-B4FC-4240-B53E-1493113271F3Q28267571-0117ABA8-E110-408C-9983-1BA863C160FEQ30496381-53C2431A-923B-4C62-B473-3F853AAF155AQ30498403-04A91D09-C712-4E08-9648-C06E264C0B06Q31894371-344EE938-70BA-4CFD-BA51-DF5E9C7F862FQ33595339-91D7BEA9-AA2D-45B3-9D63-8ED64FEAC938Q33664150-AEAEDBC0-750C-44CE-B4F4-3EB907A1D1F3Q33705502-7479FED6-5114-4B7F-918B-D4CB10488F03Q33709755-2BB4B7EF-7425-43DE-B010-55D804877675Q33709767-3E3D2087-24F0-46E1-AD7C-D2FD4C2DE346Q33729339-9A7523C5-4966-4861-81FB-F53637BA7192Q33836716-2D3AEC3F-DAD0-4801-9567-9A534B0C00AEQ33836719-FF289A3A-A1A8-49AD-8FE6-51210C13F8C3Q33836740-DEE80B15-5DC5-42E1-B3F9-6553F2A6F4EDQ33914371-1ACA0416-3FCB-454F-95D4-3960607D6D05Q34112541-95FCC889-C9F5-4506-8E14-2156F663599BQ34291204-E7A8E37F-D8F2-4062-BD92-0E63B707B650Q34318516-73626E3F-5C24-494B-A112-7C8F985BF440Q34391700-BAC147AA-695B-4679-9B68-A4397A5B93BFQ34491824-523DAF95-D5F6-4136-B2D4-3E6C5DA494A2Q34544512-EE0175E8-5E95-4EA4-87ED-6BFF42154F51Q34558685-73F2A2A7-119C-4D43-865E-B13FE5E5C7DDQ34720407-CC9F7D31-4BF0-496F-8809-16A3AC332095Q34881155-B4DFE6FB-A6A2-45ED-B210-7AB9DF210A5EQ35028002-43645DF7-D2A6-47C9-A267-02CF4887CE12Q35030801-EC3260EA-0C6C-40F5-8C5E-9C4372B720C6Q35076739-32149567-1081-4644-A299-95C26F225366Q35113606-696C3FA6-3317-410D-96AB-E4AB7BA5457CQ35129653-98C8F753-8F4D-4EBA-94BF-2865349CC269Q35532197-445BC8FF-A2E6-4CC5-A097-674CDC76F0E5Q36026021-662B0D28-C795-4B3E-8584-133DA812A86FQ36050690-E89A98CF-B018-4CDD-940A-3492708FF4DCQ36091759-92D86D25-3EBC-48C9-9E5B-027879779E0AQ36371018-24E2379B-C3D8-4CD4-8D2C-DC55C62ABBE3Q36489831-42839B82-C81F-4BE3-B667-813BAB082D74Q36724773-EB164739-63B5-4B8A-971D-AAE162AD304BQ37157003-9DCAA9A6-D40D-41E6-A763-B6269B892455Q37619192-468DF94D-0BA7-4818-BB39-84CD6B37E5EAQ37742100-4554139A-1A6F-43CF-B8F4-9F5084564982
P2860
Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Combined antagonism of leukotr ...... way obstruction in asthmatics.
@en
Combined antagonism of leukotr ...... way obstruction in asthmatics.
@nl
type
label
Combined antagonism of leukotr ...... way obstruction in asthmatics.
@en
Combined antagonism of leukotr ...... way obstruction in asthmatics.
@nl
prefLabel
Combined antagonism of leukotr ...... way obstruction in asthmatics.
@en
Combined antagonism of leukotr ...... way obstruction in asthmatics.
@nl
P2093
P1476
Combined antagonism of leukotr ...... way obstruction in asthmatics.
@en
P2093
S E Dahlén
P304
P356
10.1164/AJRCCM.155.6.9196086
P407
P577
1997-06-01T00:00:00Z